Transforming growth factor-βs and vascular disorders

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 8, 2006, Pages 1712-1720

  Bobik, Alex ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Atherosclerosis; BMP; Hereditary hemorrhagic telangiectasia; Pulmonary hypertension; Restenosis; Signaling; TGF ; Vascular cells

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; NEUTRALIZING ANTIBODY; NOGGIN; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANGIOGENESIS; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; COLLAGEN SYNTHESIS; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE; RESTENOSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VASCULAR DISEASE; ANIMAL; GENETICS; METABOLISM; MUTATION; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; HUMANS; MUTATION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR DISEASES;

EID: 33746829275     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000225287.20034.2c     Document Type: Short Survey

References (99)

1. Sluijter JPG, Verloop RE, Pulskens WPC, Velema E, Grimbergen JM, Quax PH, Goumans MJ, Pasterkamp G, de Kleijn PV. Involvement of furin-like proprotein convertases in the arterial response to injury. Cardiovasc Res. 2005;68:136-143.
2. Reddi AH. Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development: noggin, chordin and DAN. Arthritis Res. 2001;3:1-5.
3. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI, Knaus P. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem. 2002;277:5330-5338.
4. ten Dijke P, Hill CS. New insights into TGF-β-Smad signaling. Trends Biochem Sci. 2004;29:265-273.
5. Ebisawa T, Fukuchi M, Murakami G, Ghiba T, Tanaka K, Imamura T, Miyazono K. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J Biol Chem. 2001;276:12477-12480.
6. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J. 2002;21:1743-1753.
7. Ota T, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, Miyazono K. Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-β in human umbilical vein endothelial cells. J Cell Physiol. 2002;193:299-318.
8. Valdimarsdottir G, Goumans MJ, Rosendahl A, Brugman M, Itoh S, Lebrin F, Sideras P, ten Dijke P. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation. 2002;106:2263-2270.
9. Watabe T, Nishihara A, Mishima K, Yamashita J, Shimizu K, Miyazawa K, Nishikawa SI, Miyazono K. TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol. 2003;163:1303-1311.
10. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P. Activin receptor-like kinase (ALK) 1 is an antagonist mediator of lateral TGF-β/ALK5 signaling. Mol Cell. 2003;12:817-828.
11. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-β receptors II and I. J Biol Chem. 2002;277:29197-29209.
12. Yamagami S, Yokoo S, Mimura T, Amino S. Effects of TGF-β2 on immune response-related gene expression profiles in the human corneal endothelium. Invest Ophthalmol Vis Sci. 2004;45:515-521.
13. Agrotis A, Samuel M, Prapas G, Bobik A. Vascular smooth muscle cells express multiple type I receptors for TGF-β, activin and bone morphogenetic proteins. Biochem Biophys Res Commun. 1996;219:613-618.
14. Seay U, Sedding D, Krick S, Hecker M, Seegar W, Ieickelberg O. TGF-β-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent. J Pharmacol Exp Ther. 2005;315:1005-1012.
15. Khanna A. Concerted effect of transforming growth factor-β, cyclin inhibitor p21 and c-myc on smooth muscle cell proliferation. Am J Physiol. 2004;286:H1133-H1140.
16. Feinberg MW, Watanabe M, Lebedeva MA, Depina AS, Hanai J, Mammoto T, Frederick JP, Wang XF, Sukhatme VP, Jain MK. Transforming growth factor-β1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem. 2004;279:16388-16393.
17. Samarakoon R, Higgins CE, Higgins SP, Kutz SM, Higgins PJ. Plasminogen activator inhibitor type-I gene expression and induced migration in TGF-β1-stimulated smooth muscle cells is pp60(c-Src)/MEK-dependent. J Cell Physiol. 2005;204:236-246.
18. Hocevar BA, Prunier C, Howe PH. Disabled-2 (Dab2) mediates transforming growth factor β (TGFβ)-stimulated fibronectin synthesis through TGFβ-activated kinase ! and activation of the JNK pathway. J Biol Chem. 2005;280:25920-25927.
19. Ashcroft GS. Bidirectional regulation of macrophage function by TGF-β. Microbes Infect. 1999;1:1275-1282.
20. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE. Transforming growth factor β enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci U S A. 1993;90:4577-4581.
21. Ashcroft GS, Yang X, Glcik AB, Weinstein M, Letterio JL, Mizel DE, anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol. 1999;1:260-266.
22. Sato K, Kawasaki H, Nagayama H, Enomoto M, Morimoto C, Tadokoro K, Juji T, Takahashi TA. TGF-β1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J Immunol. 2000;164:2285-2295.
23. Turner M, Chantry D, Feldmann M. Transforming growth factor β induces the production of interleukin 6 by human peripheral blood mononuclear cells. Cytokine. 1990;2:211-216.
24. Panousis CG, Evans G, Zuckerman SH. TGF-β increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells: opposing the effects of IFN-γ. J Lipid Res. 2001;42:856-863.
25. Irvine SA, Foka P, Rogers SA, Mead JR, Ramji DP. A critical role for the Ap1-binding sites in the transforming growth factor-mediated inhibition of lipoprotein lipase gene expression in macrophages. Nucleic Acids Res. 2005;33:1423-1434.
26. Werner F, Jain MK, Feinberg MW, Sibinga ES, Pellacani A, Wiesel P, Chin MT, Topper JN, Perrella MA, Lee ME. Transforming growth factor-β1 inhibition of macrophage activation is mediated via Smad3. J Biol Chem. 2000;275:36653-36665.
27. Mitani T, Terashima M, Yoshimura H, Nariai Y, Tanigawa Y. TGF-β1 enhances degradation of IFN-γ-induced iNOS protein via proteasomes in RAW264.7 cells. Nitric Oxide. 2005;13:78-87.
28. Dai Y, Datta S, Novotny M, Hamilton TA. TGFβ inhibits LPS-induced chemokine mRNA stabilization. Blood. 2003;102:1178-1185.
29. Gorelik L, Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171-181.
30. Nakao A, Miike S, Hatano M, Okumura K, Tokuhisa T, Ra C, Iwamoto I. Blockade of transforming growth factor β/smad signaling in T cells by overexpression of smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med. 2000;192:151-158.
31. Cottrez F, Groux H. Regulation of TGF-β response during T cell activation is modulated by IL-10. J Immunol. 2001;167:773-778.
32. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol. 2002;2:933-944.
33. Ogawa K, Chen F, Kim YJ, Chen Y. Transcriptional regulation of tristetraprolin by transforming growth factor-β in human T cells. J Biol Chem. 2003;278:30373-30381.
34. Li MO, Wan YY, Sanjabi S, Robertson AKL, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
35. Ronger-Savle S, Valladeau J, Claudy A, Schmitt D, Peguet-Navarro J, Dezutter-Dambuyant C, Thomas L, Jullien D. TGF-β inhibits CD1d expression on dendritic cells. J Invest Dermatol. 2005;124:116-118.
36. Schramm C, Huber S, Protschka M, Czochra P, Burg J, Schmitt E, Lohse AW, Galle PR, Blessing M. TGF-β regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo. Int Immunol. 2004;16:1241-1249.
37. Raida M, Clement JH, Leek RD, Ameri K, Bicknell R, Niederweiser D, Harris AL. Bone morphogentic protein (BMP-2) and induction of tumour angiogenesis. J Cancer Res Clin Oncol. 2005;131:741-750.
38. Sorescu GP, Song H, Tressel SL, Hwang J, Dikalov S, Smith DA, Boyd NL, Platt MO, Lassegue B, Griendling KK, Jo H. Bone morphogenetic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004;95:773-779.
39. Kiyono M, Shibuya M. Bone morphogenetic protein4 mediates apoptosis of capillary endothelial cells during rat pupillary membrane regression. Mol Cell Biol. 2003;23:4627-4636.
40. Dorai H, Vukicevic S, Sampath TK. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol. 2000;184:37-45.
41. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, Atkinson C, Chen H, Trembath RC, Morrell NW. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005;96:1053-1063.
42. Bobik A, Agrotis A, Kanellakis P, Dilley R, Krushinsky A, Smirnov V, Tararak E, Condron M, Kostolias G. Distinct patterns of transforming growth factor-β isoforms and receptor expression in human atherosclerotic lesions. Colocalisation implicates TGF-β in fibrofatty lesion development. Circulation. 1999;99:2883-2891.
43. Cipollone F, Fazia M, Mincione G, Iezzi A, Pini B, Cuccurullo C, Ucchino S, Spigonardo F, Di Nisio M, Cuccerullo F, Mezzetti A, Porreca E. Increased expression of transforming growth factor-β1 as a stabilizing factor in human atherosclerotic plaques. Stroke. 2004;35:2253-2257.
44. McCaffrey TA, Consigli S, Du B, Falcone DJ, Sanborn TA, Spokojny AM, Bush HL Jr. Decreased type II/type I TGF-β receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-β. J Clin Invest. 1995;96:2667-2675.
45. Kalinina N, Agrotis A, Antropova Y, Ilyinskaya O, Smirnov V, Tararak E, Bobik A. Smad expression in human atherosclerotic lesions: evidence for impaired TGF-β/Smad signaling in smooth muscle cells of fibrofatty lesions. Arterioscler Thromb Vasc Biol. 2004;24:1391-1396.
46. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression. Arterioscler Thromb Vasc Biol. 1991;11:1223-1230.
47. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamate C, Merval R, Fradelizi D, Tedgui A. Inhibition of TGF-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001;89:930-934.
48. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwels P, Kotlaiansky VE, Daemen MJ. TGF-β mediates a balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol. 2002;22:975-982.
49. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-β in T cells accelerates atherosclerosis. J Clin Invest. 2003;112:1342-1350.
50. Veillard NR, Steffens S, Burger F, Pelli G, Mach F. Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler Thromb Vasc Biol. 2004;24:2339-2344.
51. Ait-Oufella H, Salomon BL, Potteaux S, Roberston AKL, Gourdy P, Zoll J, Merval R, Espopsito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12:178-180.
52. Fahlen L, Read S, Gorlik L, Hurst SD, Coffman RL, Flavell RA, Powrie F. T cells that cannot respond to TGFβ escape control by CD4+CD25+ regulatory T cells. J Exp Med. 2005;201:737-746.
53. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005;201:1061-1067.
54. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809.
55. Dhore CR, Cleutjens JOM, Lutgens E, Cleutjens KBJM, Geusens PPM, Kitslaar PJEHM, Tordoir JHM, Spronk HMH, Vermeer C, Daemen MJAP. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1998-2003.
56. King KE, Iyemere VP, Weissberg PL, Shanahan CM. Kruppel-like factor 4 (KLF4/GKLF) is a target of bone morphogenetic proteins and transforming growth factor β1 in the regulation of vascular smooth muscle phenotype. J Biol Chem. 2003;278:11661-11669.
57. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 2003;23:489-494.
58. Hao H, Hirota S, Ishibashi-Ueda H, Kushiro T, Kanmatsuse K, Yutani C. Expression of matrix Gla protein and osteonectin mRNA by human aortic smooth muscle cells. Cardiovasc Pathol. 2004;13:195-202.
59. Wu XB, Li Y, Schneider A, Yu W, Rajendren G, Iqbal J, Yamamotot M, Alam M, Brunet LJ, Blair HC, Zaidi M, Abe E. Impaired osteoblastic differentiation, reduced bone formation and severe osteoporosis in noggin-overexpressing mice. J Clin Invest. 2003;112:924-934.
60. Davies MR, Lund R, Kruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol. 2003;14:1559-1567.
61. Ward MR, Agrotis A, Kanellakis P, Dilley R, Jennings G, Bobik A. Inhibition of protein tyrosine kinases attenuates increases in expression of transforming growth factor-β isoforms and their receptors after arterial injury. Arterioscler Thromb Vasc Biol. 1997;17:2461-2470.
62. Assoain RK, Sporn MB. Type β transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol. 1986;102:1217-1223.
63. Hoying JB, Yin M, Diebold R, Ormsby I, Becker A, Doetschman T. Transforming growth factor β1 enhances platelet aggregation through a non-transcriptional effect on the fibrinogen receptor. J Biol Chem. 1999;274:31008-31013.
64. Wassmer SC, de Souza JB, Frere C, Candal FJ, Juhan-Vague I, Grau GE. TGF-β1 released from activated platelets can induce TNF-stimulated human brain endothelium apoptosis: a new mechanism for microvascular lesion during cerebral malaria. J Immunol. 2006;176:1180-1184.
65. Pollman MJ, Naumovski L, Gibbons GH. Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-β1 in endothelial cells versus smooth muscle cells. Circulation. 1999;99:2019-2026.
66. Ikeda Y, Imai Y, Kumagai H, Nosaka T, Morikawa Y, Hisaoka T, Manabe I, Maemura K, Nakaoka T, Imamura T, Miyazono K, Komuro I, Nagai R, Kitamura T. Vasorin, a transforming growth factor β-binding protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. Proc Natl Acad Sci U S A. 2004;101:10732-10737.
67. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, et al. Direct transfer of transforming growth factor-β1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993;90:10759-10763.
68. Yamamoto K, Morishita R, Tomita N, Shimozato T, Nakagami H, Kikuchi A, Aoki M, Higaki J, Kaneda Y, Ogihara T. Ribozyme oligonucleotides against transforming growth factor-β inhibited neointimal formation after vascular injury in rat model. Circulation. 2000;102:1308-1314.
69. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A. Tranilast prevents activation of transforming growth factor system, leukocyte accumulation and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol. 2002;22:940-948.
70. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63:515-524.
71. Khalil N, Xu YD, O'Connor R, Duronio V. Proliferation of pulmonary interstitial fibroblasts is mediated by TGF-β induced release of extracellular FGF-2 and phosphorylation of p38MAPK and JNK. J Biol Chem. 2005;280:43000-43009.
72. Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, Karwande SV, Stringham JC, Bull DA, Gleich M, Kennedy TP, Hoidal JR. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Cell Mol Physiol. 2006;290:L661-L673.
73. Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D, Herron DK, Jones ML, Lampe JW, McMillen WT, Mort N, Sawyer JS, Yingling JM. Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of epithalial mesenchymal transition. Biochemistry. 2005;44:2293-2304.
74. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8:345-351.
75. Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE, Jackson CE, Porteous ME, Marxhuk DA. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet. 1997;61:60-67.
76. Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD, Elliott CG, Robbins IM, Olschewski H, McLaughlin V, Gruenig E, Kermeen F, Laitinen T, Morrell NW, Trembath RC. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet. 2003;40:865-871.
77. Berg J, Guttmacher A, Marchuk D, Porteous ME. Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin? J Med Genet. 1996;33:256-257.
78. Bourdeau A, Faughnan ME, Letarte M. Endoglin-deficient mice, a unique model to study heteritart hemorrhagic telangiectasia. Trends Cardiovasc Med. 2000;10:279-285.
79. Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet. 2000;26:328-331.
80. Sorensen LK, Brooke BS, Li DY, Urness LD. Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFβ coreceptor. Dev Biol. 2003;261:235-250.
81. Carvalho RL, Jonker L, Goumans MJ, Larsson J, Bouman P, Karlsson S, ten Dijke P, Arthus HM, Mummery CL. Defective paracrine signaling by TGFβ in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development. 2004;131:6237-6247.
82. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-β receptor function in the endothelium. Cardiovasc Res. 2005;65:599-608.
83. Letarte M, McDonald LM, Li C, Kathirkamathamby K, Vera S, Pece-Barbara N, Kumar S. Reduced endothelial secretion and plasma levels of transforming growth factor-β1 in patients with hereditary hemorrhagic telangiectasia type 1. Cardiovasc Res. 2005;68:155-164.
84. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husian M, Letarte M. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005;96:684-692.
85. Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR, Letarte M. Potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol. 2001;158:2011-2020.
86. Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, Mitchell G, Droulin E, Westermann CJJ, Marchuk DA. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia with mutations in MADH4 (SMAD4). Lancet. 2004;363:852-859.
87. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC; International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26:81-84.
88. Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot C, Coccolo F, Ventura C, Phillips JA III, Knowles JA, Janssen B, Eickelberg O, Eddahibi S, Herve P, Nichols WC, Elliott G. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004;43(suppl 12):33S-39S.
89. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Blcoh KD. BMPR-II heterozygous mice have mild pulmonary hypertension and impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol. 2004;287:L1241-L1247.
90. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder E, Rodman DM. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res. 2004;94:1109-1114.
91. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis. 1986;134:342-346.
92. Launay JM, Herve P, Peoch K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med. 2002;8:1129-1135.
93. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic proteins. Circulation. 2001;104:790-795.
94. Machado RD, Rudarakanchana N, Atkinson C, Flanagan JA, Harrison R, Morrell NW, Trembath RC. Functional interaction between BMPR-II and Tctex-1, a light chain of dynein, is isoforms-specific and disrupted by mutations underlying primary pulmonary hypertension. Hum Mol Genet. 2003;12:3277-3286.
95. Wong WK, Knowles JA, Morse JH. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src. Am J Respir Cell Mol Biol. 2005;33:438-446.
96. Foletta V, Lim MA, Soosairaiah J, Kelly AP, Stanely EG, Shannon M, He W, Das S, Massague J, Bernard O. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol. 2003;162:1089-1098.
97. Harrison RE, Berger R, Haworth SG, Tulloh R, Mache CJ, Morrell NW, Aldred MA, Trembath RC. Transforming growth factor-β receptor mutations and pulmonary arterial hypertension in childhood. Circulation. 2005;111:435-441.
98. Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A. The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signaling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol. 2006;147:164-174.
99. Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of smad3 and its effects on transforming growth factor-β1-induced extracellular matrix expression. Mol Pharmacol. 2006;69:597-607.